Still in testing. Hematologists treating sickle cell disease default to infusion or medication, especially in emergent care. Both of these come with significant complications. One of Terumo BCT’s flagship devices uses an exchange of healthy donor red blood cells with the patients’ diseased cells. The outcomes are less complicated and procedures are more readily adaptable to individual patients.